Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Numbness, tingling, or burning in the feet of a person with diabetes can quickly raise concern about diabetic peripheral neuropathy. However, another explanation deserves attention: long-term metformin use can contribute to vitamin B12 deficiency. Low B12 levels may cause neurologic symptoms that resemble or contribute to diabetic neuropathy. Current American Diabetes Association guidance recommends considering periodic vitamin B12 assessment in people receiving long-term metformin, particularly when anemia or peripheral neuropathy is present. Therefore, checking for a potentially correctable deficiency can be an important part of evaluating new or worsening neurologic symptoms.
Table of Contents
- Why B12 deficiency with metformin use deserves attention
- When numbness may have another explanation
- Who may need vitamin B12 assessment
- Identifying and managing low vitamin B12
- Conclusion
- Frequently asked questions
Why B12 Deficiency With Metformin Use Deserves Attention
Metformin remains a widely used treatment for type 2 diabetes because of its established glucose-lowering benefits and long history of clinical use. Still, vitamin B12 deficiency is a recognized concern with long-term therapy. The American Diabetes Association Standards of Care note an association between metformin use and an increased risk of vitamin B12 deficiency.
The concern becomes especially relevant because vitamin B12 supports normal neurologic function and red blood cell production. When levels become inadequate, patients can develop symptoms such as numbness, tingling, weakness, fatigue, or other neurologic changes. Consequently, some manifestations can overlap with those commonly associated with diabetes.
Long-term evidence also supports an association between metformin exposure and lower B12 levels. In the Diabetes Prevention Program Outcomes Study, low vitamin B12 was more common among participants assigned to metformin than placebo at the five-year assessment. In addition, greater cumulative metformin exposure was associated with an increased risk of deficiency.
Dose may matter as well. A multicenter study of 1,027 people taking at least 1,000 mg of metformin daily found that patients receiving at least 1,500 mg per day had a higher prevalence of borderline-low B12 than those receiving lower doses. However, individual risk varies, so dose alone cannot determine whether a patient has vitamin B12 deficiency.
When Numbness May Not Be Only Diabetic Neuropathy
Diabetic peripheral neuropathy commonly causes numbness, burning, pain, or altered sensation, particularly in the feet. Yet diabetes should not automatically be considered the only explanation.
The ADA advises clinicians to consider causes of neuropathy other than diabetes. These include vitamin B12 deficiency, particularly among people treated chronically with metformin, as well as thyroid disease, kidney disease, alcohol exposure, certain medications, and other nutritional deficiencies.
This distinction matters because vitamin B12 deficiency in people taking metformin is potentially treatable. Moreover, a patient can have more than one contributor to neuropathy at the same time. Diabetes and low vitamin B12 are not mutually exclusive explanations.
Symptoms alone may not clearly distinguish the two conditions. For example, tingling or loss of sensation in the feet could fit either diagnosis. Therefore, clinical history, medication exposure, examination, and appropriate laboratory testing can provide valuable context.
Clinicians should also pay attention when neurologic findings seem atypical for standard diabetic peripheral neuropathy. According to ADA guidance, features such as acute or subacute onset, asymmetry, motor involvement, or a non-length-dependent pattern may warrant further evaluation.
Who Should Be Assessed for Vitamin B12 Deficiency?
There is no reason to assume that every patient taking metformin has vitamin B12 deficiency. Nevertheless, certain situations should increase clinical awareness.
The ADA Standards of Care recommend considering periodic vitamin B12 assessment in people receiving long-term metformin therapy, especially those who have anemia or peripheral neuropathy. This makes new numbness, tingling, burning, or sensory loss particularly relevant during medication review.
Higher metformin doses may also deserve attention. Research has found associations between larger daily doses and lower B12 levels. For example, one study found that metformin dose remained significantly associated with vitamin B12 deficiency after adjustment for several potential confounding factors.
Other risk factors can coexist. Dietary patterns low in vitamin B12, gastrointestinal disorders, prior gastric or small-bowel surgery, and certain medications may influence B12 status. Therefore, clinicians should consider the complete patient picture rather than metformin exposure in isolation.
Importantly, patients should not stop metformin simply because they are concerned about vitamin B12. Instead, suspected deficiency should prompt an appropriate clinical assessment. Metformin continues to have an important role in diabetes management, while B12 deficiency can often be addressed without abandoning effective glucose-lowering therapy.
Identifying and Managing Low Vitamin B12
When deficiency is suspected, serum vitamin B12 testing is generally an appropriate starting point. However, interpretation may require clinical judgment, especially when results are borderline and neurologic symptoms are present.
Additional laboratory evaluation may sometimes help clarify the diagnosis. At the same time, clinicians should assess other possible causes of neuropathy rather than assuming that a low or borderline B12 level explains every symptom.
When vitamin B12 deficiency is confirmed, treatment depends on its severity, symptoms, underlying cause, and the patient's ability to absorb B12. Oral supplementation may be appropriate in some cases, while other patients may require a different replacement strategy. Follow-up testing can then help determine whether levels respond appropriately.
Most importantly, recognizing metformin-associated vitamin B12 deficiency offers an opportunity to address a potentially reversible contributor to neurologic symptoms. That is particularly valuable when numbness has otherwise been attributed solely to diabetes.
For clinicians, the practical message is simple: when a patient taking long-term metformin develops new or worsening numbness, consider vitamin B12 deficiency before attributing the symptoms solely to diabetic neuropathy.
Conclusion
Metformin is an established and valuable therapy for many people with type 2 diabetes, but long-term use is associated with an increased risk of vitamin B12 deficiency. Because vitamin B12 deficiency can cause neurologic symptoms that overlap with diabetic peripheral neuropathy, clinicians should consider B12 status when evaluating numbness or tingling in patients taking long-term metformin.
Periodic vitamin B12 assessment is particularly worth considering in metformin-treated patients with anemia or peripheral neuropathy. Identifying B12 deficiency in a patient taking metformin does not mean the medication must automatically be discontinued. Instead, recognizing and treating a correctable deficiency may help clinicians address an important contributor to a patient's symptoms while maintaining appropriate diabetes management.
Frequently Asked Questions
Can metformin cause vitamin B12 deficiency?
Long-term metformin use is associated with an increased risk of low vitamin B12 levels. The ADA recommends considering periodic B12 assessment, particularly in patients with anemia or peripheral neuropathy.
Can vitamin B12 deficiency feel like diabetic neuropathy?
Yes. Vitamin B12 deficiency can cause neurologic symptoms such as numbness and tingling that may overlap with diabetic peripheral neuropathy. For this reason, vitamin B12 deficiency is one of the alternative causes clinicians should consider when evaluating neuropathy in a patient with diabetes.
Who is at greater risk of B12 deficiency while taking metformin?
Risk may increase with longer exposure and higher metformin doses, although individual factors also matter. Dietary intake, gastrointestinal conditions, previous gastrointestinal surgery, and other medications can also affect vitamin B12 status.
Should patients stop metformin if their B12 level is low?
Patients should not stop prescribed metformin without discussing the decision with their healthcare professional. Vitamin B12 deficiency can often be treated while diabetes therapy is appropriately managed.
When should vitamin B12 levels be checked in someone taking metformin?
The ADA recommends considering periodic assessment during long-term metformin therapy, especially when anemia or peripheral neuropathy is present. New or worsening numbness, tingling, or other neurologic symptoms may also provide a reason to evaluate B12 status as part of a broader clinical assessment.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.